Sepsis

E5 Murine Monoclonal Antiendotoxin Antibody Treatment on Trial

Published in Monoclonal Antibodies Weekly, May 17th, 2000

Researchers from the United States evaluated E5 murine monoclonal antiendotoxin antibody for the treatment of gram-negative sepsis in a randomized controlled trial.

"Context, knowledge, and understanding of gram-negative sepsis have grown over the past 20 years, but the ability to treat severe sepsis successfully has not," wrote D.C. Angus and colleagues, University of Pittsburgh, Pennsylvania.

Angus et al. published their study in the Journal of the American Medical Association ("E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis - A randomized controlled trial," JAMA, 2000;283(13):1723-1730).

The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Monoclonal Antibodies Weekly

Source: Monoclonal Antibodies Weekly (2000-05-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry